Kornimate/medical-research-clean huggingface dataset:
the impact of zinc supplementation on innate immunity and patient safety in sepsis

Conditions: Sepsis

Summary: sepsis is the body's response to a life-threatening infection. this study will determine if zinc supplementation is safe to use in patients with severe sepsis or septic shock. this study will also gather preliminary information to evaluate the impact that zinc has on the immune system (the body's defense system against infection) and whether zinc can help monocytes and macrophages (specific types of cells that remove infections from the body) work more effectively.

previous research has shown that zinc supplementation reduces the length and severity of some types of medical infections (examples include the cold virus and diarrhea). because zinc has been shown to improve the immune system's function, some doctors provide mineral supplements such as zinc to their patients in the intensive care unit. however, there are no studies to show how effective zinc is or that have evaluated what dose(s) of zinc are safe in patients with severe sepsis/septic shock. nor have studies examined if tolerable doses for septic patients can improve how the immune system functions. if zinc is shown to improve how the immune system functions during sepsis, it could be used in the future as part of the treatment regimen for patients with sepsis.

Eligibility criteria:
inclusion criteria: * admitted to an ohio state university medical center medical intensive care unit * ≥ 18 years * have consensus criteria for severe sepsis (two of four systemic inflammatory response syndrome \[sirs\] signs \[tachycardia, tachypnea, fever or hypothermia, leukocytosis or leukopenia\]) and a known or suspected infection resulting in an organ failure (i.e. respiratory failure, renal failure, etc.) * patient must consent to enrollment within 36 hours of a new episode of sepsis and be able to receive supplementation within 12 hours of enrollment but not to exceed 36 hours since sepsis onset to be eligible. exclusion criteria: * consent not available or declined, * prisoner, women who are pregnant or lactating * chemotherapy within past 4 weeks or absolute neutrophil count\<500 * aids defining illness or cluster of differentiation 4 \< 200 * acute pancreatitis or amylase/lipase \> 2x normal * small bowel obstruction or gi condition preventing enteral route of feeding * c.difficile colitis or active diarrhea * active vomiting or current use of total parenteral nutrition within past 30 days * predicted icu length of stay \< 72 hours or moribund * end stage renal disease on chronic intermittent dialysis * previously enrolled in this zinc supplementation study or currently enrolled in another nutritional supplementation trial.
comparison of subjective balance tests

Conditions: Balance; Posture

Summary: there is many subjective balance tests to evaluate static and dynamic balance. but, there is no sufficient information about which balance test is the most sensitive test to evaluate balance. therefore, the aim of this study is to compare of sensitivity of the subjective balance tests with an objective system.

in the clinical setting, many balance tests are used for evaluating balance in individuals. these tests are utilized to assess both static and dynamic balance. however, sufficient research has not been conducted to decide which subjective balance test is more sensitive than the other tests. therefore, the aim of this study is to compare of sensitivity of the subjective balance tests with an objective system.

Eligibility criteria:
inclusion criteria: * at least 18 years, * to be a volunteer to participate exclusion criteria: * orthopedic problems affecting gait and stance * visual, auditory, orientational problems that could affect study results, * walking with assist device * having a neurological disorders

Keywords: balance limits of stability postural sway
stretching exercises on hamstring flexibility.

Conditions: Hamstring Muscle; Flexibility

Summary: the hamstrings muscles are examples of muscle groups that have a tendency to shorten. limited flexibility has been shown to predispose a person to several musculoskeletal overuse injuries and significantly affect a person's function.

the objective of this study will be to compare the effect of three different methods of stretching techniques on the flexibility of hamstring muscle in subjects with short hamstring syndrome. hypotheses: there will be no difference between sub-occipital muscle inhibition technique, neuro-dynamic slump stretch, or passive hamstring stretch on hamstring flexibility in subjects with short hamstring syndrome. research question: is there is any difference between suboccipital muscle inhibition technique, neurodynamic slump stretch, or passive hamstring stretch on hamstring flexibility in patients with short hamstring syndrome?

Eligibility criteria:
inclusion criteria: * undergraduate female students * body mass index 18-25 kg/cm square. * all subjects will be free from injury or disease expected to affect hamstring length or ability to perform the exercises. exclusion criteria: * hamstring injury within the past year. * verbal report of performing regular lower extremity. * current muscle stretching exercises. * history of neck trauma (whiplash). * history of recent fracture in any part of the body. * history of neurological or orthopedic disorders * diagnosis of a herniated disk * low back pain in the last 6 months

Keywords: hamstring stretch sub-occipital inhibition neuro-dynamic
spectral computed tomography with photon counting detector of brain and vessels.

Conditions: Tomography; Stroke

Summary: primary purpose of the study is to show wether computed tomography with photon counting detector has a diagnostic image quality as good as, or better than classic computed tomography in investigations concerning stroke work-up.

images of the skull/brain at the level of the inner ear/temporal bone and the level of nucleus lentiformis will be compared with the same patients routine brain done in tia (transient ischemic attack)/stroke workup. images of the carotid plaque will be compared with the same patients routine ct-angiogram done in tia/stroke workup.

Eligibility criteria:
inclusion criteria: * brain exam with ct and/or ct neck/brain vessels prior to this study. regarding neck-vessel imaging - carotid stenosis of 30% or more. normal kidney function. exclusion criteria: * no contraindications to iodine contrast for neck-vessel imaging with contrast.
long-term efficacy of physical therapy for tmds

Conditions: Temporomandibular Joint Disorders

Summary: physical therapy is one of the initial conservative treatments for tmd. many studies and previous studies in our department have proved that it can improve the pain, mouth opening and mandibular function of patients with tmd. however, the current research on physical therapy for tmd has a short follow-up period, which cannot prove that the patients' long-term mandibular function has improved, and few studies have analyzed the relevant factors affecting the curative effect. therefore, this study is intended to adopt a retrospective cohort study to include tmd patients who received physical therapy in our department from 2016.01-2021.12. the patients' pain, joint area noise, mandibular range of motion, mandibular function and other conditions will be followed up by remote telephone or online questionnaire, and the patients' demography, clinical symptoms, pain, oral habits, depression, anxiety, sleep status, head and neck posture and other information will be collected. the multiple regression analysis model will be used to compare and analyze the relevant factors affecting the prognosis of patients, and to intervene in advance the factors that have a significant impact on the prognosis of the disease, so as to improve the treatment effect.


Eligibility criteria:
inclusion criteria: * the first-episode tmd patients with pain, limited mouth opening and abnormal noise in the joint area; 12-80 years old; regardless of gender; the patient received physical therapy in the outpatient department; mri or cbct imaging was completed before enrollment exclusion criteria: * patients with recurrent tmd; patients who had previously undergone tmj surgery; patients with nervous system diseases, immune system diseases, tumors and other diseases that the attending physician considers unsuitable for inclusion in the study; cognitive impairment

Keywords: temporomandibular joint disorders physical therapy
programmed death ligand (pd-l1) combined with chemotherapy for patients with btc

Conditions: Biliary Tract Neoplasms

Summary: this is a randomized, open-label, parallel-group multi-center study of phase 3 study to assess the efficacy and safety of kn035 compared to standard of care (soc) gemcitabine-based chemotherapies in the treatment of participants with previously untreated locally advanced or metastatic biliary tract cancer. the primary hypothesis of this study is that participants will have a longer overall survival (os) when treated with combined therapy than soc.


Eligibility criteria:
inclusion criteria: * eighteen years and older; * histological or cytological diagnosis of unresectable or metastatic gallbladder cancer or cholangiocarcinoma; * previously untreated with systemic therapy; subjects who developed recurrent disease \>6 months after a sort of adjuvant, neoadjuvant chemotherapy could also be eligible. * liver function child-pugh a or b; * performance status of 0 or 1 on the eastern cooperative oncology group (ecog) performance status; * life expectancy of at least 12 weeks; * at least one measurable lesion per recist 1.1; * adequate organ function exclusion criteria: * specific anti-tumor treatment prior to 4 weeks; * more than 50% liver metastasis ; * patient with other serious diseases or clinical conditions, including but not limited to uncontrolled active infection etc; * history of severe hypersensitivity reaction to any monoclonal antibody or chemistry; * women who are pregnant or in the period of lactation; * patients with an active, known or suspected autoimmune disease. patients are permitted to enrol if they have vitiligo, type i diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement;
study to test the long term safety and efficacy of the beta-3 agonist mirabegron (ym178) in patients with symptoms of overactive bladder

Conditions: Urinary Bladder, Overactive

Summary: the study is intended to test the safety, tolerability, efficacy of two doses of long term once daily (qd) treatment of mirabegron in patients with symptoms of overactive bladder and secondly to compare these with active comparator.

patients who completed 178-cl-046 (nct00689104) or 178-cl-047 (nct00662909) or new patients could be enrolled in this study if eligible.

Eligibility criteria:
inclusion criteria: * patient is willing and able to complete the micturition diary and questionnaires correctly * patient has symptoms of overactive bladder for ≥ 3 months * patient experiences frequency of micturition on average ≥ 8 times per 24-hour period during the 3-day micturition diary period * patient must experience at least 3 episodes of urgency (grade 3 or 4) with or without incontinence, during the 3-day micturition diary period exclusion criteria: * patient is breastfeeding, pregnant, intends to become pregnant during the study, or of childbearing potential, sexually active and not practicing a highly reliable method of birth control * patient has significant stress incontinence or mixed stress/urge incontinence where stress is the predominant factor * patient has an indwelling catheter or practices intermittent self-catheterization * patient has diabetic neuropathy * patient has evidence of a symptomatic urinary tract infection, chronic inflammation such as interstitial cystitis, bladder stones, previous pelvic radiation therapy or previous or current malignant disease of the pelvic organs * patient receives non-drug treatment including electro-stimulation therapy * patient has severe hypertension * patient has a known or suspected hypersensitivity to tolterodine, other anticholinergics, ym178, other beta-adrenoreceptor (ß-ar) agonists, or lactose or any of the other inactive ingredients * patient has been treated with any investigational drug or device within 30 days (90 days in the uk for all clinical studies except 178-cl-046) * patient had an average total daily urine volume \> 3000 ml as recorded in the 3-day micturition diary period * patient has serum creatinine \>150 umol/l, aspartate aminotransferase (ast) and/or alanine aminotransferase (alt) \> 2x upper limit of normal range (uln), or gamma-glutamyl transpeptidase (γ-gt) \> 3x uln * patient has a clinically significant abnormal electrocardiogram (ecg)

Keywords: frequency overactive bladder urgency urinary urge incontinence urinary incontinence micturition
dedicated breast pet/mri in evaluation of extent of disease in women with newly diagnosed breast cancer

Conditions: Newly Diagnosed Breast Cancer

Summary: this is a single institution study enrolling women over age 25 with newly diagnosed breast cancer and for whom a breast mr has been ordered as standard of care. subjects will undergo a hybrid dedicated breast pet/mri in lieu of a breast mri alone, for evaluation of extent of disease prior to surgical and oncologic management. the study will investigate any incremental added benefit to breast mri specificity by the addition of concurrent hybrid breast pet.

the study hypothesis is that the combination of breast pet/mri, will improve specificity and decrease the number of false positive breast biopsies recommended based on breast mri findings.

Eligibility criteria:
inclusion criteria: * women over age of 25 with newly diagnosed breast cancer and for whom a breast mr has been ordered as standard of care exclusion criteria: * male subjects * women younger than 25 * pregnant subjects * unable or unwilling to undergo mri * previous adverse reaction to 18f-fdg * unwilling to undergo biopsy of mri positive lesions
the intrathecal morphine for nephrectomy

Conditions: Renal Cell Carcinoma

Summary: to evaluate the efficacy and the safety of the intrathecal morphine injection in the open nephrectomy.

the open nephrectomy is the treatment of choice for live donor kidney transplantation and renal cell carcinoma. the incision for the nephrectomy causes severe postoperative pain. a single dose of intrathecal morphine(itm) has been used for the postoperative pain of prostatectomy, transurethral resection of the prostate and hepatectomy. the effect of itm for open nephrectomy has not been studied. therefore, this prospective, randomized study will evaluate the efficacy and safety of a single 50 mcg dose of itm added to intravenous patient controlled analgesia(iv-pca), comparing to iv-pca alone.

Eligibility criteria:
inclusion criteria: * patients scheduled for the open nephrectomy exclusion criteria: * patients with renal insufficiency * patients with coagulopathy * history of any neurologic disorder * history of recent infection in 2 weeks * history of drug abuse * patients who cannot understand the usage of th intravenous patient-controlled analgesia * patients using opioids due to the chronic pain

Keywords: injection, spinal morphine analgesia patient-controlled pain postoperative combined modality therapy nephrectomy
transfusion in sickle cell disease: screening of sickle cell disease trait in blood donors

Conditions: Sickle Cell Disease; Sickle Cell Trait

Summary: bearers of the sickle cell allele (s) are currently eligible for blood donations in belgium. as blood donors are not tested for this allele, their heterozygous status is unknown. however, guidelines recommend to transfuse sickle cell patients with blood that is negative for the 's' hemoglobin. to the investigator's knowledge, no study has been conducted to evaluate the impact of transfusion with blood originating from heterozygous donors on the transfusion performance and the improvement of clinical status of the sickle cell disease patients.


Eligibility criteria:
inclusion criteria: all patients with sickle cell disease within the chu brugmann and the queen fabiola children's hospital (huderf) exclusion criteria: none

Keywords: sickle cell heterozygous blood donor
preoperative lugol's solution in graves' disease and toxic nodular goiter

Conditions: Hyperthyroidism

Summary: the purpose of this study is to assess if preoperative treatment with lugol's solution prior to thyroidectomy can reduce the surgical complications hypoparathyroidism and laryngeal nerve palsy

current practice in sweden before thyroidectomy due to hyperthyroidism is preoperative treatment with antithyroid drugs (atd) to all patients with graves' disease and in cases of toxic nodular goiter with pronounced hyperthyroidism. iodine solution is administered preoperatively in selected cases of graves' disease where atd is intolerable. in the cases where iodine is used it is in the form of extemporaneous prepared iodine potassium iodide solution (lugol 5%). the dose varies in clinical studies. in american and swedish guidelines the dose is 5-10 drops 3 times per day for 10 days prior to surgery. american guidelines recommend iodine as preoperative treatment i graves' disease but this is based on sparse evidence. iodine as preoperative treatment in toxic nodular goiter has yet not been studied. the purpose of this study is to assess if preoperative treatment with lugol's solution prior to thyroidectomy due to hyperthyroidism reduce the surgical complications hypoparathyroidism and laryngeal nerve palsy. before including toxic nodular goiters accepted for surgery, a pilot study will be performed on 20 patients with toxic nodular goiter. they will receive lugol solution 3 times per day for ten days and thyroid hormone levels will be measured day 0, day 3-4, day 6-7 and after 10 days of lugol treatment. heart rate assessed and thypro39 filled out before and after treatment.

Eligibility criteria:
inclusion criteria: * hyperthyroidism accepted for thyroidectomy due to toxic nodular goiter with free t4 \<30 pmol/l or graves' disease * signed informed consent exclusion criteria: * unstable coronary artery disease * previous thyroid surgery * congestive heart failure * renal insufficiency * hepatic failure * current infection * treatment with steroids or anticoagulants * thyroid associated orbitopathy cas \> 2 * diabetes mellitus type 1 * active cancer * severe psychiatric illness * amiodarone treatment * pregnancy * breast feeding * women of child bearing potential not using contraceptive * inability to comprehend the meaning of the study * iodine hypersensitivity
healthy volunteers study of the effects of olanzapine and ziprasidone

Conditions: Hyperglycemia; Hyperlipidemia

Summary: primary aim: to test the acute effects of olanzapine or ziprasidone administration, in comparison to placebo, on insulin sensitivity in antipsychotic-naïve healthy young men, measured as whole-body dextrose infusion rates (mg/kg/min), hepatic glucose production (glucose rate of appearance \[ra\]), primarily muscle glucose utilization (glucose rate of disappearance \[rd\]), and adipose tissue related free fatty acid production (glycerol rate of appearance \[ra\]). we hypothesize that olanzapine, but not ziprasidone, will result in acute decreases in insulin sensitivity. secondary aim: to test the acute effects of olanzapine or ziprasidone on insulin signaling pathways in antipsychotic naïve healthy young men. we hypothesize that olanzapine, but not ziprasidone, will result in acute alterations in insulin signaling.

see brief description

Eligibility criteria:
inclusion criteria: * males aged 18-45 years * bmi approximately ≥ 25 and \< 35 * insulin approximately ≥ 15 µu/ml or triglyceride approximately ≥ 130 mg/dl exclusion criteria: * any dsm-iv axis i diagnosis * prisoners * any serious medical disorder (i.e. metabolic diseases, type 1 or 2 diabetes mellitus, endocrine disease, coagulopathy, clinically significant anemia, acute infection) * taking prescription medications * non-sedentary lifestyle with \> 3 hours of exercise per week

Keywords: healthy sedentary men acute effects of antipsychotic blood sugar insulin sensitivity
a study of emapalumab for pediatric aplastic anemia

Conditions: Aplastic Anemia; Cytopenia; Hypocellular Marrow

Summary: the purpose of this study is to find out whether upfront emapalumab treatment can help in saa (aplastic anemia) treatment planning and increase the effectiveness of standard treatment options. funding source- fda oopd


Eligibility criteria:
inclusion criteria: * patients undergoing workup for suspected newly diagnosed saa: * patients with severe cytopenias and a hypocellular marrow concerning for saa * patients that meet the definition for suspected saa (camitta criteria) as follows: marrow cellularity: \<25%, or 25-50% with \<30% residual hematopoietic cells peripheral cytopenias (at least 2 of 3) absolute neutrophil count (anc): \<500 x 10\^9/l platelets: \<20 x 10\^9/l absolute reticulocyte count: \<60 x 10\^9/l * patients that do not have evidence of leukemia or mds * patients \< 25 years of age at time of diagnosis * able to tolerate emapalumab and ist (with standard institutional organ function criteria) exclusion criteria: * uncontrolled infection at presentation. * patients who have undergone previous treatment for saa. * patients with known inherited bone marrow failure * patient who has completed a full workup for saa including having results back from telomere testing, deb and genetics (when applicable), as well as having an appropriate willing and available donor and would otherwise be admitted for hsct within 2 weeks of enrolling on the trial * patients with leukemia or mds * patient or parent or guardian unable to give informed consent or unable to comply with the treatment protocol including research tests.

Keywords: pediatric aplastic anemia aplastic anemia cytopenia hypocellular marrow emapalumab memorial sloan kettering cancer center 23-278